TEVA

Scandal-Ridden Teva Pharmaceutical Is Fishing for a Bottom

By Dana Blankenhorn, InvestorPlace Contributor
Teva's debt restructuring gives it breathing room through 2021, assuming its legal woes don't get worse. Buy Teva stock at your own risk.

The Diagnosis for Teva Stock Still Looks Grim

By Tom Taulli, InvestorPlace Contributor
Lately, Teva stock has had a nice rally, but this may prove temporary. The fact is that the company faces much uncertainty with the litigation.

9 High-Risk Stocks to Buy for Massive Rewards

By Vince Martin, InvestorPlace Contributor
A portfolio should hold high-risk, high-reward plays. And these nine stocks to buy offer big risks and even bigger potential returns.

Stay on the Sidelines as the Future Looks Potentially Bleak for Teva Stock

By Thomas Niel, InvestorPlace Contributor
With shares rebounded, now may not be the time to enter Teva stock. Wait to see how upcoming opioid trials play out. If shares pull back to prior price levels, a buying opportunity may emerge. But for now, the risks do not match up with potential upside.

Debt, Not Regulation, Is the Biggest Problem for Teva Stock

By Vince Martin, InvestorPlace Contributor
Teva stock has rallied from its lows on optimism toward legal settlements. But the balance sheet of TEVA remains an enormous risk.

Embattled TEVA Has Made Headlines for All of the Wrong Reasons

By Josh Enomoto, InvestorPlace Contributor
Teva Pharmaceuticals is under the glare of legal and regulatory scrutiny. However, TEVA will eventually find its way because frankly, it has to.

Teva Pharmaceuticals May Be a Speculator’s Dream Stock

By Will Ashworth, InvestorPlace Contributor
For risk-averse investors, TEVA stock has many questions that make it a rough pick. But for the hardened speculator, it might be worth a shot.

Teva Stock Is Nothing but Trouble after Legal Issues

By David Moadel, InvestorPlace Contributor
TEVA stock has earned its reputation - and I mean that in the worst possible way.

7 Lumbering Large-Cap Stocks to Avoid

By Louis Navellier, Editor, Growth Investor
The U.S.-China trade war is weighing on these large-cap stocks to sell. Volatile oil prices and the opioid crisis aren't helping, either.

Teva Pharmaceuticals Stock Is Safe With Settlement Talks Underway

By Chris Lau, InvestorPlace Contributor
Despite the rally, Teva stock is inexpensive. The company is working on paying off its debt and building a strong generics portfolio.

4 Top Stock Trades for Wednesday: DIS, PANW, BURL, TEVA

By Bret Kenwell, InvestorPlace Contributor
Palo Alto Networks, Burlington Stores, Teva and Disney are our top stock trades to watch going into Wednesday.

3 Recovering Healthcare Stocks to Buy That Already Escaped Flu Season

By Chris Lau, InvestorPlace Contributor
Over the past year, healthcare stocks generally lagged as markets rebounded. That's changing though, starting with these three names.

Rebounding Teva Stock Could Climb Higher, But Risks Remain

By Thomas Niel, InvestorPlace Contributor
The TEVA stock price has rebounded on a potential opioid settlement. But consider the company's other risks before buying Teva.

Why the Teva Stock Rebound May Be Real

By Luke Lango, InvestorPlace Senior Investment Analyst
TEVA stock is up 40% over the past month, and this may be just the beginning of a multi-year turnaround in the pharma giant.

With a Deal in Hand, Teva Stock Can Chart a Difficult Comeback

By Josh Enomoto, InvestorPlace Contributor
Teva stock fell sharply this year in large part thanks to the opioid crisis, but with a last-minute deal, shares look more interesting now.

2 Sells and 1 Buy in Opioid Stocks

By Chris Tyler, InvestorPlace Contributor
The opioid crisis isn’t a one size fits all indictment and right now bears and bulls can take advantage of this in WBA, JNJ and TEVA stock

Stock Market Today: Stocks Rally Ahead of Big Earnings Week

By Bret Kenwell, InvestorPlace Contributor
Another opioid settlement has been reached and earnings season is heating up. Here's what happened in the stock market today.

Stock Market Today: October Rolls in With a Bang

By Bret Kenwell, InvestorPlace Contributor
General Motors disappointed investors, while Exxon cut profit forecasts. Here's what happened in the stock market today.

7 Big Biotech Stocks to Watch

By Chris Lau, InvestorPlace Contributor
Biotech stocks are still out of favor because of macro uncertainties. But beneath that, investors may find companies trading at deep value.
Load More